Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Basecare MedicalHKSE:02170 +1.07%68 PS Ratio is 1.51 as of Aug. 17, 2026, which is 67% below its 10-year median of 4.52. GuruFocus rates HKSE:02170 with a GF Score™ of 68/100 and a GF Value™ of HK$2.95 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 801 Medical Devices & Instruments companies, Suzhou Basecare Medical ranks better than 70.04% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Suzhou Basecare Medical's share price is HK$1.42.
Suzhou Basecare Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.94. Hence, Suzhou Basecare Medical's PS Ratio for today is 1.51.
Good Sign:
Suzhou Basecare Medical Corp Ltd stock PS Ratio (=1.49) is close to 10-year low of 1.36.
The historical rank and industry rank for Suzhou Basecare Medical's PS Ratio or its related term are showing as below:
HKSE:02170'
s PS Ratio Range Over the Past 10 Years
Min: 1.36 Med: 4.52 Max: 91.97
Current: 1.52
During the past 8 years, Suzhou Basecare Medical's highest PS Ratio was 91.97. The lowest was 1.36. And the median was 4.52.
HKSE:02170's PS Ratio is ranked better than 70.04% of 801
companies
in the Medical Devices & Instruments industry
Industry Median: 3.03
vs HKSE:02170: 1.52
During the past 8 years, Suzhou Basecare Medical's highest 3-Year average Revenue per Share Growth Rate was 52.70% per year. The lowest was 17.90% per year. And the median was 33.10% per year.
Suzhou Basecare Medical (HKSE:02170) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Suzhou Basecare Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Basecare Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Suzhou Basecare Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Suzhou Basecare Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Suzhou Basecare Medical's Share Price of today is HK$1.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Suzhou Basecare Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.94.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Suzhou Basecare Medical (HKSE:02170) has a PS Ratio of 1.51 as of Aug. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Suzhou Basecare Medical and its competitors. This is 67% below median its historical median of 4.52. Over the past decade, Suzhou Basecare Medical's PS Ratio has ranged from 1.36 to 91.97. According to the industry distribution chart, Suzhou Basecare Medical ranks #240 out of 801 companies in the Medical Devices & Instruments industry, placing it in the top 30%.
Is Suzhou Basecare Medical's PS Ratio too high?
Suzhou Basecare Medical's current PS Ratio of 1.51 is 67% below median its 10-year median of 4.52. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 91.97. The Medical Devices & Instruments industry median PS Ratio is 3.03. Suzhou Basecare Medical's value of 1.51 is 50.2% below this industry median. Based on the distribution chart, Suzhou Basecare Medical ranks #240 out of 801 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Suzhou Basecare Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Suzhou Basecare Medical ranks #240 out of 801 companies for PS Ratio. This puts Suzhou Basecare Medical in the upper half of its industry. The industry median PS Ratio is 3.03. Suzhou Basecare Medical's value of 1.51 is 50.2% below this benchmark. Historically, Suzhou Basecare Medical's own PS Ratio has ranged from 1.36 to 91.97 over the past decade. While the company's 10-year median is 4.52 vs. the industry median of 3.03, Suzhou Basecare Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 3.03, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Basecare Medical's current PS Ratio of 1.51 is 50.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Suzhou Basecare Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current PS Ratio is 1.51, which is 67% below median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.95, compared to a current price of HK$1.42 — trading 51.9% below its estimated fair value. The current PS Ratio is 1.51, which is 67% below median its 10-year median of 4.52 and 50.2% below the Medical Devices & Instruments industry median of 3.03. Suzhou Basecare Medical's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current PS Ratio is 1.51 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued.
The current stock price of HK$1.42 is trading 51.9% below its estimated GF Value™ of HK$2.95.
GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.
Key valuation signals for HKSE:02170:
PS Ratio: 1.51 (67% below median its 10-year median of 4.52)
GF Value™: HK$2.95 vs. price of HK$1.42 (51.9% below fair value)
Industry Position: 50.2% below the Medical Devices & Instruments median (#240 of 801)
No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
68GF Score
Get the complete analysis for HKSE:02170
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02170 has been successfully added to your 
